Table 1.
Demographic characteristics and clinical data of the 94 subjects involved in this study.
| Donor | DBD (n = 35) | DCD (n = 12) | p-Value b | |
| Age (years) | 53 (25–82) | 56 (35–76) | 0.526 | |
| Gender (female/male) | 19/16 | 6/6 | 1 | |
| Hepatic steatosis | No | 14 | 7 | |
| Mild (<30%) | 18 | 3 | 0.305 | |
| Moderate (30–60%) | 3 | 2 | ||
| GGT (IU/L) a | 52 (6–208) | 92 (21–315) | 0.342 | |
| AST (IU/L) a | 85 (22–517) | 161 (15–392) | 0.139 | |
| ALT (IU/L) a | 72 (12–268) | 97 (13–201) | 0.623 | |
| Bilirubin (μmoL/L) a | 11 (3–37) | 12 (4–26) | 0.695 | |
| ITU stay (days) | 4 (1–28) | 4 (1–10) | 0.168 | |
| Inotrop support (Y/N) | 19/16 | 6/6 | 1 | |
| Functional WIT (min) | NA | 21 (9–33) | NA | |
| CIT (min) | 504 (210–840) | 457 (270–720) | 0.212 | |
| Recipient | DBD (n = 35) | DCD (n = 12) | p-Value b | |
| Age (years) | 44 (20–65) | 54 (46–70) | 0.029 | |
| Gender (female/male) | 13/22 | 5/7 | 1 | |
| BMI (kg/m2) | 25.8 (18.4–34.6) | 27.3 (22.1–35.8) | 0.277 | |
| MELD Score | 14.3 (2–34) | 10.7 (4–18) | 0.208 | |
| UKELD Score | 53.3 (40–77) | 51.3 (44–61) | 0.571 | |
| ALD | 9 | 3 | NA | |
| PSC | 5 | 0 | ||
| HCV | 1 | 2 | ||
| HCC | 1 | 2 | ||
| PHCC | 2 | 1 | ||
| Others d | 17 | 4 | ||
| AST (IU/L) a | 480 (10–7485) | 613 (18–5307) | 0.494 | |
| Bilirubin day 7 (μmoL/L) | 56 (7–258) | 52 (12–103) | 0.772 | |
| INR day 7 | 1.04 (0.85–1.21) | 1.06 (0.92–1.3) | 0.909 | |
| EAD/EGF | 6/29 | 4/8 | 0.251 | |
| Censored/Dead c | 22/3 | 7/2 | NA | |
DBD, donation after brain death; DCD, donation after circulatory death; GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ITU, intensive therapy unit; WIT, warm ischaemia time; CIT, cold ischaemia time; BMI, body mass index; MELD, model for end-stage liver disease; UKELD, United Kingdom model for end-stage liver disease; ALD, alcoholic liver disease; PSC, primary sclerosing cholangitis; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; PHCC, post hepatitis C cirrhosis; INR, international normalised ratio; EAD, early allograft dysfunction; EGF, early graft function. Continuous values are expressed as means (minimum–maximum); NA, not applicable. a Tested on the day of operation, b Mann–Whitney test (two-sided) or Fisher exact test (two-sided), c survival information was collected for 34 recipients, d other indications of liver transplantation include acute/chronic Wilson’s disease, metabolic disease, cholestatic disease, cryptogenic cirrhosis, polycystic disease, primary biliary cirrhosis, autoimmune cirrhosis, Alagille syndrome, hepatic malignancies, congenital biliary disease and unknow.